Tempus AI今日宣布，与Recursion Pharmaceuticals, Inc.达成重要合作升级。双方不仅延长了既有的数据许可协议，更在此基础上签署了一项全新的授权协议——聚焦于Recursion研发的RNA基础模型。
这一战略举措，标志着两家公司在生命科学和人工智能交叉领域的合作步入更深层次。通过新协议，Tempus将获得Recursion专有的RNA基础模型使用权，此举旨在进一步丰富其多模态数据能力，并强化在精准医疗领域的算法优势。
市场分析人士认为，此次合作不仅体现了数据资产在药物研发中的核心价值，也凸显了两家AI制药先锋企业间互补共赢的商业逻辑。协议的具体财务条款暂未对外披露。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.